Viyash Scientific share price jumps 17% on Q4 FY26

Rally follows Q4 earnings update

Shares of Viyash Scientific Ltd rallied in Wednesday’s trade after the company reported its earnings for the quarter ended March 31, 2026. The stock rose as much as 17.51% in early trade to a day’s high of ₹269. At last check during the session, it was trading 12.41% higher at ₹257.30. The move capped a strong run for the counter, which was up nearly 24% over the past month as per the same update. The trigger was a set of quarter-on-quarter and year-on-year improvements across key profitability metrics disclosed in stock exchange filings released after market hours on Tuesday.

Revenue growth stood out in Q4 FY26

For Q4 FY26, Viyash Scientific reported consolidated revenue from operations of ₹919.96 crore, up 19.1% year-on-year from ₹772.31 crore in the same quarter last year. The revenue jump was accompanied by a sharper expansion in operating profitability. EBITDA came in at ₹200.1 crore, a 63.9% year-on-year increase. The company also reported a meaningful margin uptick, indicating that operating performance improved faster than topline growth during the quarter.

Profit swing reflected in PAT and net profit

Below the operating line, filings highlighted a strong change in profitability versus the year-ago period. Overall profit after tax (PAT) rose to ₹66.38 crore compared with a loss of ₹32.18 crore in the corresponding quarter of the previous fiscal year. Net profit attributable to shareholders was reported at ₹52.11 crore. Taken together, these numbers point to a quarter where the company moved from losses to profits at the consolidated level, which typically draws market attention in smaller and mid-sized pharma names.

EBITDA margin expanded by 590 basis points

The company said EBITDA margins expanded by 590 basis points to 21.7% in Q4 FY26. The combination of higher revenue and stronger margins helped explain why the market reaction was sharp immediately after the earnings update. Margin expansion of this magnitude usually implies a change in mix, better utilisation, tighter cost control, or a combination of factors, though the filing details provided in the shared text focus mainly on the outcome rather than specific cost drivers.

Balance sheet deleveraging: net debt to EBITDA at 0.2x

Alongside the profit turnaround, investors also tracked the reported improvement in leverage. Viyash Scientific’s net debt to EBITDA ratio improved to 0.2x in Q4 FY26 from 1.0x in Q4 FY25. A lower leverage ratio can strengthen the investment case when earnings are improving because it can reduce financial risk and expand flexibility for future spending. Management also referenced a “significantly deleveraged balance sheet” while discussing next steps.

Management commentary: integration and selective inorganic options

Managing Director and Group CEO Hari Babu Bodepudi said in the exchange filing that FY2026 was a “transformative year” for Viyash Scientific, marked by the successful integration of facilities, operations, and corporate functions into “one unified platform.” He also said that as the company enters FY27, it is “excited” about its product pipeline and growth roadmap. With deleveraging in place, management said it is actively evaluating “selective inorganic opportunities” to strengthen the platform and create long-term value. The statement frames the quarter’s numbers as part of a broader integration-led reset, rather than a one-off spike.

Price check: what the stock traded at on 19 May 2026

Separate price snapshots in the provided data show how the stock traded later, on 19 May 2026. The share price is reported around ₹228 to ₹229, with one line stating “current share price” at ₹229.45 and another showing ₹228.73 as of 19 May 2026 at 15:58. Intraday details for the same day included an open of ₹228.02 versus a previous close of ₹225.48, a high of ₹232.99, and a low of ₹225.55. Technical reference points listed include a 50-day moving average (50 DMA) of 203.79 and a 200-day moving average (200 DMA) of 202.58.

Ratings and technical narratives remained mixed

The dataset also includes third-party technical and rating notes that describe changing momentum. It mentions a transition from a sideways trend to a bullish stance supported by “positive technical indicators,” even as an overall Mojo Grade was noted as downgraded to “Sell” in one instance. Another entry states Viyash Scientific’s investment rating was downgraded from Hold to Sell as of 5 May 2026, while a separate April sequence includes a MarketsMOJO upgrade from Sell to Hold on 9 April 2026. These snapshots indicate that despite strong quarterly numbers, external models can still flag valuation or trend-related risks depending on timing and methodology.

Key numbers at a glance

Why this earnings print mattered for the stock

The immediate share price reaction tracked a cleaner Q4 picture: higher revenue, strong EBITDA growth, margin expansion, and a reported swing to profit at the PAT level versus the year-ago loss. The leverage metric moving to 0.2x from 1.0x added a balance-sheet angle to the story, aligning with management’s positioning around integration and deleveraging. However, later price snapshots around ₹228 to ₹233 also show that post-result momentum can cool as the market absorbs broader inputs like technical ratings, sector moves, and risk appetite.

Conclusion

Viyash Scientific’s Q4 FY26 results showed a 19.1% rise in revenue to ₹919.96 crore, EBITDA of ₹200.1 crore with a 21.7% margin, and PAT of ₹66.38 crore versus a year-ago loss, alongside lower leverage at 0.2x net debt to EBITDA. Management said the company has completed major integration work and is evaluating selective inorganic opportunities as it enters FY27. Investors will track subsequent updates for clarity on the pipeline, any inorganic steps, and whether margin and profit improvements sustain beyond the quarter.